Expert Commentary

Breast cancer chemoprophylaxis in high-risk women: How persistent is the impact of an aromatase inhibitor after 5 years of use?

Author and Disclosure Information

Among postmenopausal women at high risk for breast cancer, those treated with anastrozole (N = 1,920) compared with placebo (N = 1,944) for 5 years had a 49% reduction in breast cancer (85 vs 165 cases; hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.39–0.66; P<.0001) after a median follow-up of 131 months. The reduction was larger in the first 5 years but remained significant after 5 years. Although the risk reduction from this endogenous estrogen-minimizing medication was persistent, no mortality benefit was observed.


 

References

Cuzick J, Sestak I, Forbes JF, et al; IBIS-II Investigators. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet. 2020;395;117-122.

EXPERT COMMENTARY

A manufacturer-sponsored trial initiated in 2003, IBIS-II (International Breast Cancer Intervention Study II) included 3,864 menopausal women (mean age at baseline, 59.4 years) at elevated risk for breast cancer. The women were randomly assigned to 5-year treatment with either placebo (N = 1,944) or the aromatase inhibitor anastrozole 1 mg daily (N = 1,920).1

Reporting on the long-term follow-up results of the trial, Cuzick and colleagues found that anastrozole use substantially reduced the incidence of all breast cancer, including invasive breast cancer and ductal carcinoma in situ. Key adverse events associated with anastrozole were fractures, arthralgias, and menopausal symptoms (vasomotor symptoms and vaginal dryness).

To determine whether anastrozole had any persistent impact, the investigators continued to follow participants for all breast cancers and other outcomes.2

Details of the study

This randomized controlled trial that included 3,864 postmenopausal women had a median overall follow-up of 131 months; the primary outcome was all breast cancer. Random assignment to anastrozole use (1,920 women) was associated with a 49% reduction in all breast cancer (85 cases vs 165 cases in the placebo group [N = 1,944]; HR, 0.51; 95% CI, 0.39–0.66; P<.0001).

In the first 5 years, risk reduction was 61% with anastrozole (P<.0001 for overall and the first 5 years of follow-up). Subsequently, the magnitude of the risk reduction attenuated to 37% (P = .014). With 12 years of follow-up, the estimated risk of being diagnosed with breast cancer was 8.8% and 5.3% in the placebo and anastrozole groups, respectively. The number needed to treat for 5 years to prevent 1 breast cancer was 29.

With anastrozole, prevention of estrogen–receptor positive tumors was substantially more robust at 54% (HR, 0.46; 95% CI, 0.33–0.65; P<.0001) than for estrogen–receptor negative tumors at 27% (HR, 0.77; 95% CI, 0.41–1.44; P = .41).

Over the course of the long-term study, the incidence of fractures and cardiovascular events was similar in the placebo and anastrozole groups. Arthralgias and menopausal symptoms were not assessed after the trial’s initial 5 years. Overall, the number of deaths (all cause as well as breast cancer related) were similar in the placebo and anastrozole groups.

Continue to: Study strengths and limitations...

Pages

Recommended Reading

Diet, exercise don’t improve breast cancer-related lymphedema
MDedge ObGyn
USPSTF recommends preventive breast cancer medications only for women at risk
MDedge ObGyn
Ovarian function suppression gains support for premenopausal breast cancer
MDedge ObGyn
Gene recurrence score helps predict successful combination therapy for early breast cancer
MDedge ObGyn
USPSTF recommendations on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer
MDedge ObGyn
Bisphosphonates turn 50
MDedge ObGyn
Supplemental MRI found to benefit women with dense breast tissue
MDedge ObGyn
Bilateral mastectomy reduces second breast cancer risk, but not deaths
MDedge ObGyn
Insurance coverage mediates racial disparities in breast cancer
MDedge ObGyn
Should supplemental MRI be used in otherwise average-risk women with extremely dense breasts?
MDedge ObGyn